XENOMETRIX INC \DE\
10KSB, EX-27, 2000-09-28
LABORATORY ANALYTICAL INSTRUMENTS
Previous: XENOMETRIX INC \DE\, 10KSB, 2000-09-28
Next: AMERIPRIME FUNDS, 24F-2NT, 2000-09-28



<TABLE> <S> <C>


<ARTICLE>         5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM June 30,
2000 FINANCIAL STATEMENTS OF XENOMETRIX, INC. AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER>      1,000

<S>                                                                         <C>
<PERIOD-TYPE>                                                               YEAR
<FISCAL-YEAR-END>                                                    JUN-30-2000
<PERIOD-START>                                                        JUL-1-1999
<PERIOD-END>                                                         JUN-30-2000
<CASH>                                                                       553
<SECURITIES>                                                                   0
<RECEIVABLES>                                                                 19
<ALLOWANCES>                                                                   4
<INVENTORY>                                                                   26
<CURRENT-ASSETS>                                                             701
<PP&E>                                                                     1,245
<DEPRECIATION>                                                               960
<TOTAL-ASSETS>                                                             1,417
<CURRENT-LIABILITIES>                                                        928
<BONDS>                                                                        0
<COMMON>                                                                       3
                                                          0
                                                                    0
<OTHER-SE>                                                                   486
<TOTAL-LIABILITY-AND-EQUITY>                                               1,417
<SALES>                                                                      214
<TOTAL-REVENUES>                                                           1,875
<CGS>                                                                        387
<TOTAL-COSTS>                                                                660
<OTHER-EXPENSES>                                                             688
<LOSS-PROVISION>                                                               0
<INTEREST-EXPENSE>                                                             8
<INCOME-PRETAX>                                                              527
<INCOME-TAX>                                                                   0
<INCOME-CONTINUING>                                                          527
<DISCONTINUED>                                                                 0
<EXTRAORDINARY>                                                                0
<CHANGES>                                                                      0
<NET-INCOME>                                                                 527
<EPS-BASIC>                                                                 0.17
<EPS-DILUTED>                                                               0.16



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission